Whether your personal interests are in supporting innovation, bringing lifesaving biomedical products to patients, training the next generation of biomedical leaders or fueling our economy, the Center for Biotechnology provides a vehicle to accomplish great things. Things that matter. Things that change, and save, lives.
Your involvement is an essential part of our future. Please consider a gift to the Center for Biotechnology which will help fuel innovation by ensuring that lifesaving technologies make it out of research labs and into the hands of patients.
Give to the Center for Biotechnology online through the Stony Brook Foundation. Contributions can be made to our Fund for Excellence. More information about donating through the Stony Brook Foundation can be found here.
Sustained Nano Systems Reports Positive In-Vitro Results Glaucoma Treatment
March 8, 2018
SUSTAINED NANO SYSTEMS ACHIEVES POSITIVE IN-VITRO RESULTS ON LONG TERM SUSTAINED DELIVERY OF LATANAPROST FOR GLAUCOMA TREATMENT.
New York, NY – March 6, 2018 (NEWSFRONT MEDIA). Sustained Nano Systems, LLC (“SNS”), a biopharmaceutical company utilizing its platform technology of bio-resorbable nano and microparticles for long term drug delivery, is pleased to announce positive results for the in-vitro presence of Latanaprost for the treatment of glaucoma over a duration of 159 days.
Latanaprost, a prostaglandin analogue, is the #1 glaucoma drug in the world, with dosing of up to four eye drops every day for the remainder of a patient’s life. Latanaprost reduces elevated intraocular pressure in open-angle glaucoma or ocular hypertension. At the present time, there is no long-acting formulation for glaucoma, only multiple daily eyedrops. SNS LAT-LA (Latanaprost Long Acting) is designed to be administered by a single periocular injection with a duration of six months. “The potential for SNS LAT-LA to sustain deliver for six months, would fulfill an important unmet need in replacing the more burdensome and potentially less compliant regimen of daily eye drops,” said Dr. Barry Libin, CEO of SNS. LAT-LA will now undergo further studies to indicate its efficacy in the long term reduction of intra-ocular pressure.
Glaucoma is the second leading cause of blindness in the world, in which abnormally high intraocular pressure may cause damage to the optic nerve, resulting in irreversible vision loss. In the U.S. alone, 2.7 million people suffer from glaucoma. According to IMS Health data, there were 34 million prescriptions and sales of over $2.7 billion of drugs administered by eye drops for the treatment of glaucoma in the U.S. in 2017, and global spending was over $6 billion. Compliance is the biggest problem with existing therapies for glaucoma, with more than 50% of patients on topical prostaglandin analogs not compliant within the first six months of treatment
ABOUT SUSTAINED NANO SYSTEMS (SNS)
SNS is a privately held biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions in ophthalmology, oncology and other areas. The Company’s research facility is located on the campus of Stony Brook University as part of the Long Island High Technology Incubator. The SNS platform is the result of a comprehensive research effort that allows for long term micro-dosing for the continuous release of drugs to targeted tissues as prescribed. The basis of the SNS pipeline is its patented technology that incorporates bio-resorbable nano and micro carriers to deliver sustained delivery of important therapeutics, including anti-inflammatories and monoclonal antibodies for immunotherapies in cancer, retinal disease, and other disease states.
Forward-Looking Statements
SNS Disclosure Notice: This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein or which are otherwise made by or on behalf of the Company that are not statements of historical facts may be deemed forward looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “to,” “plan,” “expect,” “believe,” “anticipate,” “intend,” “could,” “should,” “would,” “estimate,” or “continue,” or the negative or other variations thereof or comparable terminology are intended to identify forward looking statements. Investors are cautioned that all forward looking statements involve risk and uncertainties which may cause results to differ materially from those set forth in the statements. Such risks and uncertainties include, but are not limited to the following: the success of research and development activities and the speed with which regulatory authorizations and product launches may be achieved; government regulation generally; competitive developments; the ability to successfully market products domestically and internationally; difficulties or delays in manufacturing or issues relating to manufacturing capacity; commercial obstacles to the successful introduction of brand products generally; legal defense costs, insurance expenses, settlement costs, and the risk of an adverse decision or settlement relating to product liability, patent protection, governmental investigations, and other legal proceedings; the Company’s ability to acquire and protect patents and other intellectual property both domestically and internationally; the absence of certainty regarding the receipt of required regulatory approval or the timing or terms of such approvals; any changes in business, political and economic conditions; business interruption due to hurricanes or other events outside of the Company’s control.
Investors are cautioned not to place reliance on these forward-looking statements, which are valid only as of the date they were made. The Company undertakes no obligation to update or revise any forward-looking statements to reflect new information or the occurrence of unanticipated events or otherwise, except as expressly required by law.
Contact:
Dr. Barry Libin (516) 353‐7983, barlibin@gmail.com
Media Relations: info@newsfrontmedia.com
The Redesignation brings $10 million in funding to drive innovation, company formation, and economic growth.
The Center for Biotechnology (CFB) has announced its re-designated as a Center for Advanced Technology (CAT) by Empire State Development's Division of Science, Technology and Innovation (NYSTAR), a recognition that comes with $1 million in annual funding over the next ten years. The $10 million commitment underscores the CFB’s leadership in accelerating life science innovation, supporting early-stage technology development, and fueling economic growth through start-up formation and industry partnerships.
“The Center for Biotechnology has served as a critical bridge between academic research and commercial success,” said Dr. Clinton Rubin, Director of the Center for Biotechnology. “This re-designation ensures we can continue to expand our impact, helping innovators bring breakthrough technology to market and strengthening New York’s position as a leader in the bioscience industry.”
Empire State Development President, CEO and Commissioner Hope Knight said, “NYSTAR’s Centers for Advanced Technology are vital to our strategic efforts to grow New York’s economy and the state’s greater innovation ecosystem. By investing in the industries of tomorrow, New Yorkers benefit today through dynamic partnerships that help to create new jobs, generate more revenues, and encourage more companies to establish a footprint in communities all throughout the state.”
The Center for Biotechnology is located on the campus of Stony Brook University (SBU), the flagship research institution within the prestigious State University of New York (SUNY) system. Stony Brook University is recognized as a national and global leader in life sciences research, biomedical innovation, and clinical care. Situated on Long Island, New York, Stony Brook has built a formidable reputation as a hub for cutting-edge scientific discovery and translational medicine. The Center for Biotechnology builds upon these strengths by providing cutting-edge programming and competitive financial support to advance biomedical innovation and emerging company growth.
“We are excited to build upon the successful foundation of strong entrepreneurial networks, infrastructure, and programming that we have built over the last four decades” said Dr. Diane Fabel, Chief Operating Officer at the Center for Biotechnology. “The impacts we have had during our last designation period include over $1B in total economic impact with more than 1000 jobs created, and driving more than $315M in follow-on funding. We are excited to see those numbers continue to grow when we celebrate fifty years of hard work at the end of this redesignation period”.
As part of the New York State CAT program, the CFB will continue to work with emerging and established companies across the state to de-risk early-stage technologies, advance both technology and company value, foster public-private collaboration, and provide critical infrastructure for the region’s growing life science ecosystem. Additionally, the CFB team will continue its efforts to develop a life sciences workforce to support the region's bio-innovation economy with a specific emphasis on sectors deemed important to the NYS economy.
[post_title] => Center for Biotechnology Announces Redesignation as New York State Center for Advanced Technology
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => redesignation2025
[to_ping] =>
[pinged] =>
[post_modified] => 2025-07-21 14:51:44
[post_modified_gmt] => 2025-07-21 18:51:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4906
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 4488
[post_author] => 4
[post_date] => 2024-10-24 10:45:00
[post_date_gmt] => 2024-10-24 14:45:00
[post_content] =>
Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.
The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.
New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.
A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.
New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.
[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park
[to_ping] =>
[pinged] =>
[post_modified] => 2025-02-26 16:35:20
[post_modified_gmt] => 2025-02-26 21:35:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4488
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 4231
[post_author] => 4
[post_date] => 2023-07-10 12:37:00
[post_date_gmt] => 2023-07-10 16:37:00
[post_content] =>
SBU Startup, Lahara Bio, presented in the start-up stadium event at the 2023 BIO International Convention in June.
Christopher Ashdown, a MD/PhD student at Stony Brook University, and Center for Biotechnology Program alumnus presented on behalf of Lahara after securing a spot in the coveted forum by winning multiple pitch competitions from NIH SEED office.
According to Ashdown, “Bio 2023 was an amazing experience, and I was thrilled to be able to share the exciting work that we're doing at Lahara Bio with the greater bioscience community. The CfB was incredibly helpful in preparing the company for this conference and has done an excellent job of helping me develop on a personal/professional level".
In addition to the main stage presentation, Ashdown also presented Lahara Bio at the NIH booth. Lahara Bio was sponsored to attend BIO by the NIH after Ashdown won the national investor pitch competition at the NIH Proof of Concept Network annual meeting this past spring.
Lahara Bio is an early-stage biotechnology company using cell-specific mechanical vibration to non-invasively improve biomanufacturing outcomes. Learn more about the company and the team behind Lahara at laharabio.com.
[post_title] => Lahara Bio Presents at BIO International Convention
[post_excerpt] => Stony Brook Start Up, Lahara Bio, was presented at the 2023 BIO International Convention by Christopher Ashdown, a MD/PhD student at Stony Brook University, and Center for Biotechnology Program alumnus.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => lahara-bio-presents-at-bio-international-convention
[to_ping] =>
[pinged] =>
[post_modified] => 2024-08-22 11:32:58
[post_modified_gmt] => 2024-08-22 15:32:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4231
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 2482
[post_author] => 4
[post_date] => 2016-11-18 01:16:24
[post_date_gmt] => 2016-11-18 01:16:24
[post_content] => Program Established to Foster Vibrant Bioscience Cluster in the Region
On Friday, November 18th at the Long Island High Technology Incubator, the Long Island BioMentor Initiative (LIBMI) will be hosting its first full-day mentor training session for the founding mentors of the new initiative. Led by the Center for Biotechnology at Stony Brook University and Accelerate Long Island, the LIBMI has been established on behalf of the Long Island Bioscience Hub - an NIH-designated Research, Evaluation, and Commercialization Hub. The LIBMI is a platform to bring highly qualified, volunteer mentors together with motivated, early-stage bioentrepreneurs to provide guidance and support as they advance their business strategy.
The LIBMI is based on the successful mentoring model developed at the Massachusetts Institute of Technology’s (MIT) Venture Mentoring Service (VMS), and created in collaboration with Stony Brook University, Brookhaven National Laboratory, Cold Spring Harbor Laboratory, Hofstra University, and the Feinstein Institute at Northwell Health Systems. Through MIT VMS’s team mentoring approach, the LIBMI aims to provide objective and unbiased advice that will help entrepreneurs navigate the challenging landscape that growing bioscience ventures face. Mentors participating in the November 18th training session led by a MIT VMS Co-Director will benefit from curriculum and interactive teachings along with a mentoring session with one of the first entrepreneurs chosen to serve as mentee.
“There is an abundance of innovation on Long Island as well as a growing pool of entrepreneurs looking to create ventures that will take root and grow in the region” said Mark Lesko, Board Member, Accelerate Long Island. Diane Fabel, Director of Operations for the Center for Biotechnology added “Establishing a formal mentoring program, specifically for the bioscience sector, is critical as these companies need diverse support in order for them to thrive.”
The initiative employs the team mentoring approach and brings together experts with great depth and a range of experiences. The members of the founding mentor team include Dr. Linda Amper, Chief People Officer of Clever Devices; Dr. Gian Luca Araldi, founder and principal of US Pharma Services; Kara Cannon, Global Head of Sales & Marketing of Enzo Life Sciences, Inc.; Dr. Anil Dhundale, former Executive Director of the Long Island High Technology Incubator; Dr. Wayne Koff, President and CEO of Human Vaccines Project; Ric Overton, President of Overton Operations Advisors; Jeff Peacock, VP Global Quality Assurance and Regulatory Affairs at Henry Schein, Inc.; Dr. Saied Tousi, Managing Director for NW Advisors; and Edward Travaglianti, Market President of Long Island for TD Bank.
The entire process is guided by a statement of principles to ensure confidentiality and a conflict free environment. The initiative will build upon a suite of services and resources provided by the NIH-designated Research, Evaluation, and Commercialization Hub (LI Bioscience Hub), Accelerate Long Island and the Emerging Technology Fund, the New York State Center for Advanced Technology in Medical Biotechnology.
“It’s important to me to help support the entrepreneurial ecosystem on Long Island” founding mentor Ed Travaglianti stated, “and the team approach expands our capacity, allowing us to mentor more than one entrepreneur.”
Learn more about the Long Island BioMentor Initiative here.
[post_title] => Long Island Biomentoring Initiative Established
[post_excerpt] => On Friday, November 18th at the Long Island High Technology Incubator, the Long Island BioMentor Initiative (LIBMI) will be hosting its first full-day mentor training session for the founding mentors of the new initiative. The LIBMI is a platform to bring highly qualified, volunteer mentors together with motivated, early-stage bioentrepreneurs to provide guidance and support as they advance their business strategy.
[post_status] => publish
[comment_status] => closed
[ping_status] => open
[post_password] =>
[post_name] => long-island-biomentoring-initiative-established
[to_ping] =>
[pinged] =>
[post_modified] => 2016-12-30 18:08:16
[post_modified_gmt] => 2016-12-30 18:08:16
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2482
[menu_order] => 161
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[4] => WP_Post Object
(
[ID] => 1417
[post_author] => 3
[post_date] => 2015-02-19 19:17:30
[post_date_gmt] => 2015-02-19 19:17:30
[post_content] => Presented by Clean Energy Business Incubator ProgramWednesday, March 11, 2015
Long Island High Tech Incubator
3:30 PM - 5:00 PM: Seminar
5:00 PM - 7:00 PM: Mixer
In most cases for a startup, having patent, trade secret, trademark, and/or copyright protection is the key leverage needed to attract the life-blood investment necessary to sustain and grow the startup to exit. This discussion will address from a startup's perspective how to maintain the maximum potential value of Intellectual Property you may have AND future Intellectual Property that you don't even know about yet!
You will learn about:
Patent, Trademark, Copyright and Trade Secret Basics
Common misconceptions about IP, e.g., Patentability and enforcement vs. Freedom-to-Operate
Preparing for your pitch and the resultant Due Diligence
What steps to take (or not to take) in order to avoid losing your precious IP leverage: Unintentionally forfeiting IP rights,Controlling ownership,And other IP portfolio building strategies
Speakers: Ray Farrell, founding partner of Carter, DeLuca, Farrell & Schmidt, LLP; Pina Campagna, Patent & Trademark Attorney at Carter, DeLuca, Farrell & Schmidt, LLP.
RSVP to David C Hamilton Director, Business Development, Clean Energy Business Incubator Program (CEBIP): david.hamilton@stonybrook.edu
[post_title] => Startup Mission Critical: How to build an IP portfolio investors will want to invest in early and often
[post_excerpt] => In most cases for a startup, having patent, trade secret, trademark, and/or copyright protection is the key leverage needed to attract the life-blood investment necessary to sustain and grow the startup to exit.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => startup-mission-critical-how-to-build-an-ip-portfolio-investors-will-want-to-invest-in-early-and-often
[to_ping] =>
[pinged] =>
[post_modified] => 2016-03-02 18:02:01
[post_modified_gmt] => 2016-03-02 18:02:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/new/?p=1417
[menu_order] => 214
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 5
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 4906
[post_author] => 4
[post_date] => 2025-07-17 10:27:09
[post_date_gmt] => 2025-07-17 14:27:09
[post_content] =>
The Redesignation brings $10 million in funding to drive innovation, company formation, and economic growth.
The Center for Biotechnology (CFB) has announced its re-designated as a Center for Advanced Technology (CAT) by Empire State Development's Division of Science, Technology and Innovation (NYSTAR), a recognition that comes with $1 million in annual funding over the next ten years. The $10 million commitment underscores the CFB’s leadership in accelerating life science innovation, supporting early-stage technology development, and fueling economic growth through start-up formation and industry partnerships.
“The Center for Biotechnology has served as a critical bridge between academic research and commercial success,” said Dr. Clinton Rubin, Director of the Center for Biotechnology. “This re-designation ensures we can continue to expand our impact, helping innovators bring breakthrough technology to market and strengthening New York’s position as a leader in the bioscience industry.”
Empire State Development President, CEO and Commissioner Hope Knight said, “NYSTAR’s Centers for Advanced Technology are vital to our strategic efforts to grow New York’s economy and the state’s greater innovation ecosystem. By investing in the industries of tomorrow, New Yorkers benefit today through dynamic partnerships that help to create new jobs, generate more revenues, and encourage more companies to establish a footprint in communities all throughout the state.”
The Center for Biotechnology is located on the campus of Stony Brook University (SBU), the flagship research institution within the prestigious State University of New York (SUNY) system. Stony Brook University is recognized as a national and global leader in life sciences research, biomedical innovation, and clinical care. Situated on Long Island, New York, Stony Brook has built a formidable reputation as a hub for cutting-edge scientific discovery and translational medicine. The Center for Biotechnology builds upon these strengths by providing cutting-edge programming and competitive financial support to advance biomedical innovation and emerging company growth.
“We are excited to build upon the successful foundation of strong entrepreneurial networks, infrastructure, and programming that we have built over the last four decades” said Dr. Diane Fabel, Chief Operating Officer at the Center for Biotechnology. “The impacts we have had during our last designation period include over $1B in total economic impact with more than 1000 jobs created, and driving more than $315M in follow-on funding. We are excited to see those numbers continue to grow when we celebrate fifty years of hard work at the end of this redesignation period”.
As part of the New York State CAT program, the CFB will continue to work with emerging and established companies across the state to de-risk early-stage technologies, advance both technology and company value, foster public-private collaboration, and provide critical infrastructure for the region’s growing life science ecosystem. Additionally, the CFB team will continue its efforts to develop a life sciences workforce to support the region's bio-innovation economy with a specific emphasis on sectors deemed important to the NYS economy.
